At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CAI Caris Life Sciences, Inc.
Pre-Mkt 08-31 07:12:54 EDT
25.63
-0.75
-2.84%
盘前25.61
-0.02-0.08%
07:00 EDT
High26.75Low25.47Vol3.84M
Open26.15D1 Closing26.38Amplitude4.85%
Mkt Cap7.23BTradable Cap2.97BTotal Shares282.15M
T/O99.01MT/O Rate3.31%Tradable Shares116.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Movement Alert｜Caris Life Sciences, Inc. Falls 5.19% in Regular Trading, Trading at $26.54
Market Focus  ·  08-26
Movement Alert｜Caris Life Sciences, Inc. Falls 5.19% in Regular Trading, Trading at $26.54
Movement Alert｜Caris Life Sciences, Inc. Rises 5.01% in Regular Trading, Trading at $27.44
Market Focus  ·  08-26
Movement Alert｜Caris Life Sciences, Inc. Rises 5.01% in Regular Trading, Trading at $27.44
Movement Alert｜Caris Life Sciences, Inc. Rises 5.09% in Regular Trading, Q2 Revenue Beats Estimates by 10.7% Fueling Continued Rally
Market Focus  ·  08-21
Movement Alert｜Caris Life Sciences, Inc. Rises 5.09% in Regular Trading, Q2 Revenue Beats Estimates by 10.7% Fueling Continued Rally
Movement Alert｜Caris Life Sciences, Inc. Rises 7.89% in Regular Trading, Q2 Revenue Beat Continues to Fuel Upward Momentum
Market Focus  ·  08-21
Movement Alert｜Caris Life Sciences, Inc. Rises 7.89% in Regular Trading, Q2 Revenue Beat Continues to Fuel Upward Momentum
CAI Corp Updates Market on Unaudited Net Asset Value Per Share
TIPRANKS  ·  08-14
CAI Corp Updates Market on Unaudited Net Asset Value Per Share
Caris Life Sciences Price Target Raised to $33.00/Share from $32.00 by BTIG
Dow Jones  ·  08-07
Caris Life Sciences Price Target Raised to $33.00/Share from $32.00 by BTIG
Analysts Are Bullish on These NA Stocks: Harrow Health (HROW), Caris Life Sciences, Inc. (CAI)
TIPRANKS  ·  08-07
Analysts Are Bullish on These NA Stocks: Harrow Health (HROW), Caris Life Sciences, Inc. (CAI)
Natera Q2 Revenue Rises Beats Estimates on Higher Overall Test Volumes, Raises 2026 Outlook
Reuters  ·  08-07
Natera Q2 Revenue Rises Beats Estimates on Higher Overall Test Volumes, Raises 2026 Outlook
Caris Life Sciences up over 15%, on Pace for Record Percent Increase
Dow Jones  ·  08-06
Caris Life Sciences up over 15%, on Pace for Record Percent Increase
Lantheus Q2 Revenue Rises 2.7%, Beats Estimates
Reuters  ·  08-06
Lantheus Q2 Revenue Rises 2.7%, Beats Estimates
U.S. Research Roundup-Caterpillar, Eli Lilly, McKesson
Reuters  ·  08-06
U.S. Research Roundup-Caterpillar, Eli Lilly, McKesson
Sweden's Immunovia Q2 Sales Rise on PancreaSure Test Uptake
Reuters  ·  08-06
Sweden's Immunovia Q2 Sales Rise on PancreaSure Test Uptake
Caris Life Sciences, Inc. : JP Morgan Cuts Targt Price to $25 from $30
THOMSON REUTERS  ·  08-06
Caris Life Sciences, Inc. : JP Morgan Cuts Targt Price to $25 from $30
Caris Life Sciences, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-06
Caris Life Sciences, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Caris Life Sciences Q2 Revenue Rises 45% on the Back of Molecular Profiling Services
Reuters  ·  08-06
Caris Life Sciences Q2 Revenue Rises 45% on the Back of Molecular Profiling Services
Caris Life Sciences Q2 FY26 Net Loss Narrows to USD 0.6 Million; Revenue Rises 45% to USD 263.7 Million
Reuters  ·  08-06
Caris Life Sciences Q2 FY26 Net Loss Narrows to USD 0.6 Million; Revenue Rises 45% to USD 263.7 Million
Caris Life Sciences Q2 Sales $263.712M Beat $238.125M Estimate
Benzinga Earnings  ·  08-06
Caris Life Sciences Q2 Sales $263.712M Beat $238.125M Estimate
Caris Life Sciences Inc Q2 Net Loss Per Share $0.00
THOMSON REUTERS  ·  08-06
Caris Life Sciences Inc Q2 Net Loss Per Share $0.00
Caris Life Sciences Inc Expected to Post Earnings of 1 Cent a Share - Earnings Preview
Reuters  ·  08-04
Caris Life Sciences Inc Expected to Post Earnings of 1 Cent a Share - Earnings Preview
Earning Preview: Caris Life Sciences, Inc. Q2 revenue is expected to increase by 74.08%, and institutional views are bullish
Earnings Agent  ·  07-29
Earning Preview: Caris Life Sciences, Inc. Q2 revenue is expected to increase by 74.08%, and institutional views are bullish

Introduction

Company Name.
Caris Life Sciences, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Caris Life Sciences, Inc. is a leading patient-centered next-generation artificial intelligence technology biology company and precision medicine pioneer. It develops and commercializes innovative solutions to transform health care through the large-scale use of comprehensive molecular information and AI/ML algorithms. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology and serving the clinical, academic and biopharmaceutical markets.
Issue price:
--